Response to Miller et al: resistant mutations in CML and Ph(+) ALL - role of ponatinib.
Pfizer Oncology, Pfizer Inc., New York, NY, USA.
Nathalie
N
Bardy-Bouxin
Pfizer Oncology, Pfizer Inc., New York, NY, USA.
Ewa
E
Matczak
Pfizer Oncology, Pfizer Inc., New York, NY, USA.
Geeta
G
Devgan
Pfizer Oncology, Pfizer Inc., New York, NY, USA.
Mabel
M
Woloj
Pfizer Oncology, Pfizer Inc., New York, NY, USA.
Mark
M
Shapiro